Evidence map›Paper›PMID 32075696›Full record

ArticleGenome medicine2020

Towards a European health research and innovation cloud (HRIC).

F M Aarestrup, A Albeyatti, W J Armitage, C Auffray, L Augello, R Balling, N Benhabiles, G Bertolini, J G Bjaalie, M Black and 42 more

Abstract read
In one paragraph

Article in Genome medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Decentralised clinical trials in multiple sclerosis research.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023
    Review
  11. Article
  12. Genetic pain loss disorders.Nature reviews. Disease primers · 2022
    Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

52 authors.

F M AarestrupTechnical University of Denmark, Kongens Lyngby, Denmark.
A AlbeyattiMedicalchain, York Road, London, SQ1 7NQ, UK.
W J ArmitageTranslation Health Sciences, Bristol Medical School, Bristol, BS81UD, UK.
C AuffrayEuropean Institute for Systems Biology and Medicine (EISBM), Vourles, France. cauffray@eisbm.org.ORCID 0000-0003-2226-7411
L AugelloRegional Agency for Innovation & Procurement (ARIA), Welfare Services Division, Lombardy, Milan, Italy.
R BallingLuxembourg Centre for Systems Biomedicine, Campus Belval, University of Luxembourg, Luxembourg City, Luxembourg.
N BenhabilesCEA, French Atomic Energy and Alternative Energy Commission, Direction de la Recherche Fondamentale, Université Paris-Saclay, F-91191, Gif-sur-Yvette, France. nora.benhabiles@cea.fr.
G BertoliniIstituto di Ricerche Farmacologiche Mario Negri IRCCS, Bergamo, Italy.
J G BjaalieInstitute of Basic Medical Sciences, University of Oslo, Oslo, Norway.
M BlackUlster University, Belfast, BT15 1ED, UK.
N BlombergELIXIR, Welcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK. niklas.blomberg@elixir-europe.org.
P BogaertSciensano, Brussels, Belgium and Tilburg University, Tilburg, The Netherlands.
M BubakDepartment of Computer Science and Academic Computing Center Cyfronet, Akademia Gornizco Hutnizca University of Science and Technology, Krakow, Poland.
B ClaerhoutGhent University, Ghent, Belgium.
L ClarkeEuropean Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, CB10 1SD, UK.
B De MeulderEuropean Institute for Systems Biology and Medicine (EISBM), Vourles, France.
G D'ErricoFondazione Toscana Life Sciences, 53100, Siena, Italy.
A Di MeglioCERN, European Organization for Nuclear Research, Meyrin, Switzerland.
N ForgoUniversity of Vienna, Vienna, Austria.
C Gans-CombeINSEEC School of Business & Economics, Paris, France.
A E GrayPwC, Dronning Eufemiasgate, N-0191, Oslo, Norway.
I GutCenter for Genomic Regulations, Barcelona, Spain.
A GyllenbergNeuroimmunology Unit, The Karolinska Neuroimmunology & Multiple Sclerosis Centre, Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.
G Hemmrich-StanisakInstitute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
L HjorthDepartment of Clinical Sciences, Pediatrics, Lund University, Skåne University Hospital, Lund, Sweden.
Y IoannidisAthena Research & Innovation Center and University of Athens, Athens, Greece.
S JarmalaiteNational Cancer Institute, Vilnius, Lithuania.
A KelgeneXplain GmbH, Wolfenbüttel, Germany.
F KherifCentre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
J O KorbelEuropean Molecular Biology Laboratory, Genome Biology Unit, Heidelberg, Germany. korbel@embl.de.
C LarueIntegrated Biobank of Luxembourg, Rue Louis Rech, L-3555, Dudelange, Luxembourg.
M Laszlo.
A MaasAntwerp University Hospital and University of Antwerp, Edegem, Belgium.
L MagalhaesClinerion Ltd, Elisabethenanlage, 4051, Basel, Switzerland.
I Manneh-VangramberenEuropean Cancer Patient Coalition, Rue de Montoyer/Montoyerstraat, B-1000, Brussels, Belgium.
E Morley-FletcherLynkeus, Via Livenza, 00198, Rome, Italy.
C OhmannEuropean Clinical Research Infrastructure Network, Heinrich-Heine-Universität, Düsseldorf, Germany.
P OksvoldScience for Life Laboratory, KTH Royal Institute of Technology, Stockholm, Sweden.
N P OxtobyCentre for Medical Image Computing, Department of Computer Science, University College London, London, UK.
I PerseilInformation Technology Department, Institut National de la Santé et de la Recherche Médicale, Paris, France.
V PezoulasUnit of Medical Technology and Intelligent Information Systems, Department of Materials Science and Engineering, University of Ioannina, Ioannina, Greece.
O RiessInstitute of Medical Genetics and Applied Genomics, Rare Disease Center, Tübingen, Germany.
H RiperSection Clinical, Neuro and Developmental Psychology, Department of Behavioural and Movement Sciences, Vrije Universiteit, Amsterdam, The Netherlands.
J RocaHospital Clínic de Barcelona, IDIBAPS, University of Barcelona, Barcelona, Spain.
P RosenstielInstitute of Clinical Molecular Biology, Kiel University and University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
P SabatierFrench National Centre for Scientific Research, Grenoble, France.
F SanzHospital del Mar Medical Research Institute (IMIM), Universitat Pompeu Fabra, Barcelona, Spain.
M TayebMedicalchain, York Road, London, SQ1 7NQ, UK.
G ThomassenUniversity of Oslo, Oslo, Norway.
J Van BusselScientific Institute of Public Health, Brussels, Belgium.
M Van den BulckeScientific Institute of Public Health, Brussels, Belgium.
H Van OyenDepartment of Computer Science and Academic Computing Center Cyfronet, Akademia Gornizco Hutnizca University of Science and Technology, Krakow, Poland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrastructure. Creating a European Health Research and Innovation Cloud (HRIC) within this environment should enable data sharing and analysis for health research across the EU, in compliance with data protection legislation while preserving the full trust of the participants. Such a HRIC should learn from and build on existing data infrastructures, integrate best practices, and focus on the concrete needs of the community in terms of technologies, governance, management, regulation, and ethics requirements. Here, we describe the vision and expected benefits of digital data sharing in health research activities and present a roadmap that fosters the opportunities while answering the challenges of implementing a HRIC. For this, we put forward five specific recommendations and action points to ensure that a European HRIC: i) is built on established standards and guidelines, providing cloud technologies through an open and decentralized infrastructure; ii) is developed and certified to the highest standards of interoperability and data security that can be trusted by all stakeholders; iii) is supported by a robust ethical and legal framework that is compliant with the EU General Data Protection Regulation (GDPR); iv) establishes a proper environment for the training of new generations of data and medical scientists; and v) stimulates research and innovation in transnational collaborations through public and private initiatives and partnerships funded by the EU through Horizon 2020 and Horizon Europe.

Indexed as

Cloud ComputingDiffusion of InnovationPractice Guidelines as TopicBiomedical ResearchEuropean UnionInformation Dissemination

Identifiers

PMID32075696
PMCPMC7029532

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.